Sapien Biosciences Private Limited - Due diligence report

A 360° intelligence report on Sapien Biosciences: trust score, financial health, credit view, compliance, directors, growth and distress sig…

2012-04-12 Hyderabad, Telangana Active Unlisted Active Compliant
Share
SB Sapien Biosciences Private Limited
Full Due-Diligence Report + Documents
  • Unlock all financial figures & 5-year trends
  • Full trust, health & credit-risk scores
  • Director details, charges & MCA documents
₹700 ₹449 Save ₹251 excl. GST
Or from ₹279/report with credits View credit packages
Company Credits – Starter
  • One credit unlocks this full due-diligence report
  • Use across any company’s report, anytime
  • Credits valid for 12 months
× ₹700 ₹279 = ₹2,790 60% off
Choose your own credit amount View credit packages

Sapien Biosciences — 360° Intelligence Report

Generated from MCA filings & public records
74/100
Trust Score
Moderate

Sapien Biosciences is assessed as Moderate with a Trust Score of 74/100. Sapien Biosciences is an active private limited indian non-government company incorporated in 2012, operating in the Healthcare sector. The company has shown revenue growth across its recent filed years. It reported a loss in its latest filed year. Based on MCA filings and public records, it currently shows a low compliance risk and high financial risk profile.

Report generated on 16 Jul 2026 from the latest processed filings. Sapien Biosciences Private Limited snapshot & full profile →

Financial Health › Weak
Overall Assessment CautionWeakNeutralGoodStrong Strong
Compliance › Strong

Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.

02

Score Card

Higher is safer · rule-based & explainable
Trust ScoreModerate
74/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreLow Risk
100/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreCaution Indicated
30/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreModerate
50/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
90/100
Board strength, DIN status, churn and network.
Growth ScoreModerate
65/100
Revenue, profit, asset and hiring momentum.
Distress ScoreModerate
55/100
Early-warning signals - higher means fewer warnings.
03

Financial Intelligence Dashboard

Standalone · 5 filed year(s)

Unlock the full 5-year financial dashboard with charts and year-wise figures.

Get full access

Scores and observations on this page are already computed from the real filings - only the underlying figures are locked.

04

Credit & Compliance Intelligence

Why the scores are what they are
Credit Risk Score: 50/100 Moderate
  • Negative operating earnings - debt service depends on external support.
  • No open charges - unencumbered balance sheet.
  • Working-capital cover adequate.

Charges position: 0 open (-) · 0 satisfied (-).

Compliance Score: 100/100 Low Risk
  • Company status is Active as per MCA.
  • Annual filings current (balance sheet Mar 2025).
  • 1 active GST registration(s).
05

Director Intelligence

Stability score: 90/100
NameDIN / PANDesignationAppointedTenureDIN status
Sridhar Rohini 01234567 Director 01/04/2018 6 yrs Approved
NIRMAL KUMAR GANGULY 01234567 Director 01/04/2018 6 yrs Approved
SREEVATSA NATARAJAN GOPINATH 01234567 Director 01/04/2018 6 yrs Approved
JUGNU JAIN 01234567 Director 01/04/2018 6 yrs Approved
ISHITA SHIVELY 01234567 Director 01/04/2018 6 yrs Approved
  • 5 directors on the board.
  • No disqualified or deactivated DINs.
  • 1 director exit(s) in the last 3 years.
  • Average tenure above 5 years.
Director & KMP remuneration (FY 2023)
NameDesignationTotal remuneration
A K SharmaManaging Director2.4 cr
R MehtaWhole-time Director1.6 cr
S IyerCFO95.0 L

Remuneration is disclosed in the latest annual return. Unlock full report

06

Ownership & Group Intelligence

As per FY 2023 annual return
Promoter holding
64.27%
Public / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
Apollo Hospitals Enterprise Limited
Subsidiaries
-
Group entities
-
Capital events
6 allotment(s) · 0 transfer(s)

Promoters hold a dominant controlling stake - exact percentages are part of the full report.

Group entityRelationship% held
Apollo Hospitals Enterprise Limited Holding Company 74.00%

Full shareholding pattern, group structure & capital events →

07

Risk Intelligence Center

Growth 65 · Distress 55
Growth signals & trust indicators
Steady revenue growth: +38% over 4 year(s).
EPFO headcount growing - hiring signal.
Operating for 14+ years.
Active EPFO - real payroll on record.
Active GST registration(s).
Distress signals & risk flags
Losses deepening year-on-year.
Negative net worth.
08

Stakeholder Verdicts

Vendor · Banker · Investor
Vendor due diligence79/100
Favourable indicators
Suitability as a supplier / customer counterparty.
  • Statutory record is clean.
  • 2 distress signal(s) - see Risk Center.
  • Financial filings available for verification.
Banker assessment56/100
Mixed indicators - deeper appraisal suggested
Indicative lending comfort for banks, NBFCs and trade credit.
  • Debt capacity assessed from filed statements.
  • No existing security registered - first-charge position available.
  • Compliance record supports lending.
Investor view55/100
Mixed indicators
Growth quality and scalability through an investor lens.
  • 2 growth signal(s) detected.
  • Margin and return trends computable from filings.
  • Management team looks stable.
09

MCA Filings & Events Timeline

Latest 15 events
30 Sep 2025
Last AGM held
Annual general meeting
31 Mar 2025
Latest balance sheet
Filed with ROC
29 Sep 2024
Director ceased
Sridhar Rohini
18 May 2024
Director appointed
Sridhar Rohini (Director)
09 May 2018
Director appointed
ISHITA SHIVELY (Director)
30 Sep 2017
Director ceased
NIRMAL KUMAR GANGULY
25 Aug 2017
Director ceased
SEEMANT JAUHARI
29 Apr 2017
Director appointed
NIRMAL KUMAR GANGULY (Director)
31 Mar 2017
Securities allotted
600000 Preference Shares - 60.00 Lakh raised
10 Aug 2014
Securities allotted
970000.00 Preference Shares - 97.00 Lakh raised
21 May 2014
Securities allotted
30000.00 Preference Shares - 3.00 Lakh raised
06 Jul 2013
Securities allotted
500000.00 Preference Shares - 50.00 Lakh raised
24 Jun 2013
Director ceased
SITA NAIK
Director ceased
SREEVATSA NATARAJAN GOPINATH
Director ceased
JUGNU JAIN
10

Key Observations

Auto-generated from the data above
Revenue grew 1.42 over the last 4 financial year(s).
Net profit margin moved from 2.1x to 24%.
Compliance record is strong - status, filings and flags are clean.
5 active director(s) / partner(s); board looks stable and experienced.
1 active GST registration(s) indicate ongoing business operations.
EPFO-registered employer - verifiable payroll history exists.
Promoters hold a dominant controlling stake as per the FY 2023 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
Capital has been raised through 6 security allotment(s) - amounts available in the full report.
11

Peers & Related Companies

Full peer comparison →
CompanyCINLocation
Pv Compu Patterns Private Limited U72300TG2014PTC092460 Hyderabad, Telangana, India
Gatrad Cal-Test Laboratories And Research Private Limited U74900GJ2010PTC060031 Ahmedabad, Gujarat, India
Biospherecro U24233MH2012PTC236944 Thane, Maharashtra, India
Anvation Labs U31501TG2015PTC101081 Seri Lingampally, Telangana, India
Nova Chemdrugs Private Limited U24232MH2001PTC108616 Pune City, Maharashtra, India
Sri Ramadhootha Poultry Research Farm Private Limited U74999TG2017PTC116259 Hyderabad, Telangana, India
Cephas Life Sciences Private Limited U73100TN2019PTC130646 Chennai, Tamil Nadu, India
Expia Private Limited U72900GJ2017FTC095865 Ahmedabad, Gujarat, India
12

Who Uses This Report

CA · CS · Banker · Investor · Vendor
Chartered Accountants (CA)

Verify Sapien Biosciences before audits and certifications: compliance score 100/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.

Company Secretaries (CS)

Track statutory health of Sapien Biosciences: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.

Bankers & NBFCs

Current banker verdict: Mixed indicators - deeper appraisal suggested. Credit risk score 50/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.

Investors & Analysts

Investor view: Mixed indicators. Growth score 65/100, margin trends, ownership structure and peer set for Sapien Biosciences - screening before a deeper diligence.

Vendors & Procurement Teams

Vendor verdict: Favourable indicators. Trust score 74/100, distress signals and MSME payment-delay disclosures - know whether Sapien Biosciences pays its suppliers before you extend credit terms.

Lawyers & Compliance Teams

Litigation footprint (no cases on record), regulatory flags, charge documents trail and director networks for Sapien Biosciences - groundwork for KYC, onboarding and disputes.

13

Frequently Asked Questions

Is Sapien Biosciences an active company?

Sapien Biosciences has MCA status “Active” with a compliance score of 100/100 (Low Risk).

Is Sapien Biosciences financially healthy?

Sapien Biosciences has a Financial Health Score of 30/100 (Caution Indicated) based on its filed financial statements.

Should I do business with Sapien Biosciences?

Its overall Trust Score is 74/100 (Moderate). Vendor verdict: Favourable indicators. Review the risk flags in the Risk Intelligence Center before deciding.

Who controls Sapien Biosciences?

The ultimate holding entity is Apollo Hospitals Enterprise Limited. 5 active director(s) are on record.

Does Sapien Biosciences have loans or charges against its assets?

No charges are registered against this company - an unencumbered balance sheet.

Is Sapien Biosciences up to date with its ROC filings?

Annual filings current (balance sheet Mar 2025). Overall compliance score: 100/100 (Low Risk).

Is it risky to lend to Sapien Biosciences?

Its Credit Risk Score is 50/100 (Moderate). Banker verdict: Mixed indicators - deeper appraisal suggested.

Disclaimer: This report is generated automatically from MCA filings and public records as available in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice. Verify from official sources and consult a qualified professional before any business, lending or investment decision. If you represent this company and believe any information is inaccurate or outdated, report it here and we will review promptly.